COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Rapport financier semestriel 2025
-
COMMUNIQUÉ DE PRESSE
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Bausch Health completes acquisition of DURECT, adding larsucosterol for alcohol-associated hepatitis to its hepatology pipeline. Transaction details and future plans disclosed -
COMMUNIQUÉ DE PRESSE
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. announces participation in LSX World Congress 2025 to present revolutionary broad-spectrum antiviral drug NV-387 and potential impact on viral infections -
COMMUNIQUÉ DE PRESSE
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Revelation Biosciences, Inc. announces immediate exercise of warrants for purchase of common stock. Private placement agreement with new Class I warrants. Roth Capital Partners as financial advisor -
COMMUNIQUÉ DE PRESSE
SMX and Singapore's A*STAR Create World's First National Plastics Passport, Solving Recycling's Fatal Flaw (NASDAQ: SMX)
SMX and A*STAR introduce the world's first national plastics passport to revolutionize recycling by addressing fragmentation, inconsistent auditing, and limited scope. This innovative system uses molecular-level marking technology to provide continuous proof and expand coverage to all polymer types, transforming recycling infrastructure -
COMMUNIQUÉ DE PRESSE
SES SCORE Surpasses 600,000 of Transmission Hours, Delivering 900 Hours of Major Sports Content Daily
SES announces market momentum for SES Sports Content Orchestration Enabler (SES SCORE) platform, surpassing 600,000 transmission hours and supporting major sports content delivery worldwide -
COMMUNIQUÉ DE PRESSE
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment -
